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Abstract: Depression is a common and debilitating condition, with considerable impact for
depressed individuals and a heavy burden for society. In spite of its prevalence, depression is
underrecognized and under- or inappropriately treated. In spite of the large number of
antidepressants available at the present time, they are far from ideal and all show a similar
slow, and frequently, incomplete response. Thus, the need for new and better compounds is as
urgent and compelling as ever. While waiting for the panacea of future antidepressants,
clinicians have developed a variety of associations of several antidepressants or an
antidepressant with a second different agent. This article reviews the various strategies adopted
by clinicians in the hope of increasing the response rate of current antidepressants to obtain
full remission and/or to overcome treatment-resistant depression.
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Introduction
Although depression affects a substantial proportion of the population (Kessler et al
2003), this disease is underrecognized and, if diagnosed (APA 1994), is still frequently
inadequately or inappropriately treated. Because of the high prevalence and chronicity
of depression, a complete antidepressant response remains an important objective
for clinicians and is still a key target for new drug development (Andrade et al 2003;
Greenberg et al 2003). “Response” of a depressed patient to treatment is defined as
at least a 50% reduction in depressive symptoms evaluated on a standard instrument,
such as the Hamilton Depression Rating Scale (HAM-D) or Montgomery-Asberg
Depression Rating Scale (MADRS) (Frank et al 1991). Although clearly the symptoms
of a “responder” are improved, he or she is not “cured” or in “remission”, which is a
total absence of all symptoms of depression. Operationally, this is usually defined as a
level of depressive symptoms that fall below a threshold value such as a score of ≤ 7
on the 17-item HAM-D as recommended by Frank et al (1991). It is generally accepted
that about two thirds of patients treated for depression will respond to some extent
albeit after several weeks (2–8 weeks) (Bosker et al 2004) and a third will not respond
at all (Pérez et al 2001). Full remission, when it occurs (in about 30%–50% of treated
patients), can take 4–6 weeks up to months to achieve (Rush and Trivedi 1995; Ferrier
1999). Despite the diversity of their mechanisms of action, all current antidepressants
produce approximately the same final rates of response and remission (Artigas et al
2002). These figures speak for themselves, and the need for strategies to increase the
response rate of patients and to obtain full remission in as many patients as possible
is clear.
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When patients do not respond or respond insufficiently
to monotherapy, numerous approaches have been attempted,
some of which seem to be quite effective (Kelsey 2002; Thase
2004). These include “switching strategies” (within an
antidepressant class or between drug classes, electro-
convulsive therapy, and psychotherapy); “combination
strategies”, which involve the use of two or more different
antidepressants together; or “augmentation strategies”,
consisting of the addition of a non-antidepressant therapy
to a partially active therapy. These many treatment options
for partially or totally refractory depression are often based
on present neurobiological understanding of depression or
the mechanisms of action of antidepressants. Many more
are used in clinical practice, some with a theoretical basis,
others purely empirically.
The main pharmacological classes of antidepressants
include enzyme inhibitors (monoamine oxidase inhibitors
[MAOIs]), uptake blockers, and receptor blockers. By
dissecting these classes it is possible to reveal distinct
mechanisms of action through which the antidepressants
exert their therapeutic effect on depression when used as
monotherapy (Lieberman et al 2005) (Table 1). The principal
drugs belonging to each group of mechanism of action are
indicated in Table 1.
Antidepressant combinations
The aim of combining antidepressants is to combine two or
more mechanisms of action in an attempt to obtain a synergy
(enhancement of efficacy) or enhanced tolerability (by
opposing or blocking side effects).
Serotonergic strategy
Extensive inhibition of the reuptake of serotonin (5-
hydroxytryptamine [5-HT]) can produce a range of
serotonergic side effects experienced by some patients taking
selective serotonin reuptake inhibitors (SSRIs). Associating
extensive inhibition of 5-HT reuptake with antagonism of
5-HT2 receptors is an example of pharmacological synergy
within the serotonergic system. In the combination of SSRIs
with trazodone or nefazodone, the blockade of 5-HT2A receptors
can be beneficial since stimulation of 5-HT2A receptors
(through increased synaptic 5-HT) is responsible for the
side effects such as agitation and insomnia (see retrospective
prescription analysis of Clark and Alexander 2000).
Blockade of 5-HT2A receptors by trazodone reduces the inci-
dence of these adverse events making it possible to increase
the dose of SSRIs and boost their efficacy (Stahl 2000).
Table 1 Different antidepressants classified according to their
mechanism of action
MAOIs: Irreversible and nonselective Phenelzine
Tranylcypromine
Isocarboxazid
MAOIs: Reversible inhibitor of MAO-A Moclobemide
MAOIs: Preferential inhibitor of MAO-B Deprenyl
a
Tricyclic (and tetracyclic) antidepressants  Clomipramine
Imipramine
Amitriptyline
Nortriptyline
Protriptyline
Maprotiline
Amoxapine
Doxepin
Desipramine
Trimipramine
Selective serotonin reuptake inhibitors  Fluoxetine
Sertraline
Paroxetine
Fluvoxamine
Citalopram
Escitalopram
Selective noradrenaline reuptake inhibitors  Reboxetine
Atomoxetine
Noradrenaline and dopamine reuptake
inhibitor/releaser Bupropion
b
Serotonin and noradrenaline reuptake inhibitors  Venlafaxine
Milnacipran
Duloxetine
Serotonin antagonists/reuptake inhibitors Nefazodone
Trazodone
Alpha2-adrenoceptor antagonist Mirtazapine
Electroconvulsive therapy 
Psychotherapy
a Deprenyl at high doses also inhibits MAO-A and results in an antidepressant
action.
b Recent studies indicate that bupropion may act more by enhancing the release
of noradrenaline and dopamine than by blocking their reuptake (Dong and
Blier 2001; Gobbi et al 2003).
Noradrenergic strategy
Noradrenergic neurotransmission needs to be boosted in
some depressed patients, especially those with fatigue,
apathy, and mental and physical slowing. Theoretically a
noradrenergic boost can be expected by combining the
noradrenaline reuptake inhibitor (NRI), reboxetine, or
desipramine (tricyclic antidepressant [TCA] with a selective
noradrenaline reuptake inhibition) with bupropion, a
noradrenaline and dopamine reuptake inhibitor/releaser. As
yet, however, there are no published studies to support this
strategy (Stahl 2000).Neuropsychiatric Disease and Treatment 2005:1(4) 303
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Serotonergic and noradrenergic (and
dopaminergic) strategy
A randomized, double-blind study has shown a greater
remission in patients with major depression when combining
the SSRI, fluoxetine, and desipramine than with either
selective agent alone (Nelson et al 2004). For a subset of
depressed patients, the most refractory depressed patients,
activation of multiple neurotransmitter systems is beneficial
in achieving remission (Kelsey 2002). In such cases,
stimulating both serotonin and noradrenaline neuro-
transmission may be useful. Combinations of the serotonin
and noradrenaline reuptake inhibitor (SNRI), venlafaxine,
with mirtazapine can achieve this result in the various
treatment options of the prospective, randomized trial
described by Rush et al (2004). Mirtazapine, through its
α2-adrenoceptor blockade, potentiates noradrenaline
activity, while its 5-HT2A, 5-HT2C, and 5-HT3 receptor
antagonisms limit serotonergic side effects.
A full list of potential double (or triple)-boost 5-HT,
noradrenaline, and/or dopamine combinations are given in
Stahl (2000).
An example of a serotonergic and noradrenergic and
dopaminergic strategy is the combination of bupropion-SR
(slow release) with the SSRI, citalopram, in a naturalistic,
open-label cohort study (Lam et al 2004). Patients with
major depression who had not responded to at least 6 weeks
of treatment with citalopram or bupropion-SR were treated
by a combination of citalopram and bupropion-SR. The
combination was superior to either monotherapy in these
treatment-resistant depressed patients (Lam et al 2004).
Greater improvement has also been found in patients with
affective illness who were treated with a combination of
bupropion and a SSRI than with either agent alone
(uncontrolled clinical series, Bodkin et al 1997). In
depressed patients who partially responded to lithium
augmentation (see below) of SSRI, the further addition of a
noradrenergic antidepressant, bupropion or desipramine,
substantially improved their symptoms (open case series,
Ramasubbu 2002).
Other strategies
Electroconvulsive therapy
Electroconvulsive therapy (ECT) is highly effective for
treatment of major depression, but a high rate of relapse
after discontinuation of ECT is observed (Sackheim et al
2001). A small, retrospective case-controlled study by
Gagné et al (2000) has shown that following an acute phase
of ECT, maintenance ECT plus long-term antidepressant
treatment was more effective than an antidepressant alone.
Psychotherapy
Interpersonal and cognitive behavioral therapies have been
the best empirically supported treatments (for review, see
Chambless and Hollon 1998). Evidence is accumulating that
psychotherapy is most effective when combined with
antidepressants. Cognitive or interpersonal therapy added
to pharmacotherapy has been found to enhance the rate of
remission for patients suffering from chronic (randomized
comparative study, Keller et al 2000), severe recurrent (meta-
analysis, Thase et al 1997; randomized comparative 2-year
follow-up study, Fava et al 1998), resistant (open 2-year
follow-up trial, Fava et al 1997), or partially treatment-
responsive depressive syndromes (randomized comparative
2-year follow up study, Fava et al 1994; controlled trial,
Paykel et al 1999). This approach was particularly useful in
a fragile population of elderly depressed patients who
received maintenance therapy with nortriptyline and
interpersonal therapy that resulted in the best prophylaxis
against recurrent episodes (randomized, double-blind,
placebo-controlled trial, Reynolds et al 1999).
SAME (S-adenosyl-l-methionine)
Depressed patients who were partial and nonresponders to
SSRIs (fluoxetine, paroxetine, citalopram, escitalopram, or
sertraline) or the SNRI venlafaxine had their therapy
supplemented with S-adenosyl-l-methionine (SAME). A
response rate of 50% and a remission rate of 43% were
obtained suggesting that the combination of SAME with
antidepressants might be an effective strategy in resistant
depression (open trial, Alpert et al 2004).
Augmenting agents
Lithium and mood stabilizers
Lithium has been used for many years in the treatment of
bipolar disorder to control mania, and it has also proven to
be an effective adjunct to standard antidepressants in the
acute treatment phase of unipolar major depression (see
review of Bauer et al 2003). Studies have shown that lithium
can increase response or initiate response in nonresponders
when used in association with different types of anti-
depressants such as TCAs, MAOIs, SSRIs, and the SNRI
venlafaxine (open trial, Bertschy et al 2003). Lithium
augmentation has also demonstrated to be effective in the
continuation treatment phase to prevent early relapse. It isNeuropsychiatric Disease and Treatment 2005:1(4) 304
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thought to act on various neurotransmitter systems at the
level of signal transduction mechanisms, leading to
neuroplastic changes associated with stabilization of mood
(see the review of Lenox and Hahn 2000). Lithium also plays
a correcting role in the expression of some genes involved
in the pathophysiology of bipolar disorder. Animal studies
have shown that potentiation of antidepressant treatment by
lithium may also be mediated through enhanced 5-HT
neurotransmission (Haddjeri et al 2000). Neuroendocrine
studies in humans also demonstrate that lithium augments
the function of the serotonergic system (Bauer et al 2003).
Although mood stabilizers are usually prescribed with
antidepressants to avoid switching to mania in bipolar
patients, some are used as augmentation agents in
depression. Anticonvulsants, such as valproate,
carbamazepine (see review of Dietrich and Emrich 1998),
and lamotrigine (randomized, double-blind, placebo-
controlled study, Barbosa et al 2003), combined with
classical antidepressants appear to be well tolerated and
effective in treatment-resistant depressed patients. Recently,
venlafaxine combined with carbamazepine has proved to
be effective in the treatment of depressed patients not
responding to monotherapy with venlafaxine (open study,
Ciusani et al 2004).
Thyroid hormone
The prevalence of thyroid dysfunction in women is high.
Hypothyroidism is associated with depression, and
correcting this endocrine dysfunction is beneficial when
treating an associated depression (Larisch et al 2004). The
addition of triiodothyronine (T3) to ongoing TCA treatment
is an effective augmentation strategy in patients with
refractory depression in a randomized, double-blind,
placebo-controlled study (Joffe et al 1993) and in
accelerating clinical response to TCAs in patients with
nonrefractory depression, particularly women (meta-
analysis, Altshuler et al 2001). For example, depressed
patients unresponsive to the SSRI fluoxetine, responded to
fluoxetine associated with T3 (open-label treatment, Agid
and Lerer 2003). This augmentation effect of T3 on the
antidepressant action (at least of the tricyclics) may be
explained by the increased 5-HT levels in rat frontal cortex
after chronic administration of T3, measured by
microdialysis (Gur et al 1999). Chronic administration of
clomipramine also resulted in increased levels of 5-HT in
the frontal cortex. In rats treated with clomipramine and
T3, cortical levels of 5-HT were higher than those of rats
receiving only one treatment (Gur et al 1999).
5-HT1A receptor augmenting agents
Clinical studies and genetic research in animals and humans
have suggested that the activity of 5-HT1A receptors may
be important in the pathophysiology of depression (Celada
et al 2004; Neumeister et al 2004). The somatodendritic
5-HT1A autoreceptors located in the raphe nuclei are
stimulated by increased serotonin concentrations that result
from the inhibition of serotonin reuptake by antidepressants
such as SSRIs given acutely. This results, through a negative
feedback mechanism, in an inhibition of the firing activity
of midbrain 5-HT neurones and the release of 5-HT by
terminals in the forebrain. This leads to an attenuation of
the increase in synaptic 5-HT produced by antidepressants
in forebrain. The delayed onset of action of serotonergic
antidepressants is considered to be, at least in part, the result
of a reduction in the function, or desensitization, of 5-HT1A
somatodendritic autoreceptors, which occurs following
chronic treatment with these drugs. This delay of onset of
action is similar to the time necessary for the desensitization
of these 5-HT1A autoreceptors by the SSRIs to occur (Blier
and de Montigny 1994).
5-HT1A receptor antagonists
As explained above, only when the 5-HT1A autoreceptors
are desensitized (after several weeks) is the full potential of
serotonin reuptake inhibition obtained. The 5-HT1A receptor
antagonists can remove this feedback and have been
proposed as a means of accelerating and possibly
potentiating antidepressant action (Pérez et al 2001; Serrats
et al 2004).
The β-adrenergic/5-HT1A receptor antagonist, pindolol,
which binds to the 5-HT1A receptors in the human brain
(Martinez et al 2001; Rabiner et al 2001), accelerates and
may enhance the antidepressant effect of SSRIs (meta-
analysis of Ballesteros and Callado 2004; review of Isaac
2004), such as fluoxetine (see review of Artigas et al 2001;
controlled trial, Pérez et al 2001), or in paroxetine-refractory
patients (placebo-controlled study, Sokolski et al 2004). Not
all authors, however, have been able to replicate these
findings (double-blind, placebo-controlled trial, Berman et
al 1997). Preclinical studies that have examined the
desensitization hypothesis and clinical studies that utilized
pindolol as a test of this hypothesis in depressed patients
have been reviewed by Kinney et al (2000).Neuropsychiatric Disease and Treatment 2005:1(4) 305
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Buspirone
The partial 5-HT1A receptor agonist (full agonist at 5-HT1A
autoreceptors and partial agonist at postsynaptic 5-HT1A
receptors) buspirone, which is used principally in
generalized anxiety disorder, has also been shown to produce
marked clinical improvement when used as an augmenting
agent in depressed patients who are initially unresponsive
to the SSRIs such as fluoxetine, paroxetine, or citalopram
(open trial, Dimitriou and Dimitriou 1998; see review of
Shayegan and Stahl 2000). Results from a randomized,
double-blind, placebo-controlled study showed that severely
depressed patients had a better response when buspirone
(compared with placebo) was added to their fluoxetine or
citalopram treatment (Appelberg et al 2001). However,
another double-blind, placebo-controlled trial (Landen et
al 1998) failed to demonstrate any difference in the extra
efficacy resulting from the addition of buspirone or placebo
to their SSRI therapy. An unusually high placebo response
may explain this result.
The effect of buspirone is thought to be via enhancement
of the activation of postsynaptic 5-HT1A receptors in the
presence of 5-HT1A autoreceptors, which have already been
desensitized by the antidepressant.
Estrogen
Vulnerability to mood disorders is increased during
perimenopause and postmenopause (Soares and Cohen
2001). Because fluctuating estrogen levels accompany the
perimenopausal transition, estrogen replacement therapy
(ERT) has been suggested as a possibly effective adjunctive
treatment for mood disorders occurring during peri-
menopause (Soares and Cohen 2001). Discontinuation of
hormone therapy appears to be associated with the rapid
recurrence of depression in some women with a history of
depression (Stewart et al 2004). Small studies have shown
that in depressed women who have minimal response to a
SSRI, ERT may augment response (open trial, Rasgon et al
2002; randomized comparative study, Westlund and Parry
2003). Fluoxetine combined with ERT in a recent
randomized, open-label, parallel trial was effective in the
treatment of menopausal depressed women (Liu et al 2004).
Inhibitors of steroid synthesis
Young et al (2004) have reported that the corticosteroid
receptor antagonist mifepristone can exert an antidepressive
effect. Following these preliminary results, Jahn et al (2004)
have shown in a double-blind, placebo-controlled trial that
metyrapone, an inhibitor of cortisol synthesis and associated
with nefazodone or fluvoxamine, gives a better outcome
than the antidepressants alone, with an earlier onset of action
and a sustained effect in patients with major depression.
Methylphenidate
The antidepressant response to monotherapy is often
inadequate in the elderly and especially in patients with
extensive psychomotor slowing. The addition of a stimulant
action can be particularly beneficial in this fragile population
by accelerating and intensifying the response. The indirect
dopaminergic agonist and psychostimulant methylphenidate
(for review, see Leonard 2004) combined with MAOIs still
represents an alternative after other options have failed (see
review of Feinberg 2004; case study, Shelton Clauson 2004).
Methylphenidate has also been shown by Lavretsky et al
(2003) in an open-label trial to accelerate the response to
the SSRI citalopram in this population.
Atypical antipsychotics
In subjects with recurrent major depression (non-bipolar)
without psychotic features and who are unresponsive to
conventional antidepressant therapy, it has been
demonstrated that the efficacy of olanzapine plus fluoxetine
is superior for treating their resistant depression than either
agent alone (double-blind, comparative study, Shelton et al
2001; retrospective chart review, Barbee et al 2004). Similar
results were obtained with ziprasidone in association with
the SSRIs, fluoxetine, paroxetine, citalopram, or sertraline
(Barbee et al 2004; open trial, Papakostas et al 2004). An
augmentation therapy of milnacipran with risperidone has
been found to considerably improve recovery in patients
with depression who only partially responded to milnacipran
alone, and also in some treatment-refractory patients (case
series, Tani et al 2004). In addition, the response to the
addition of risperidone was very rapid (less than 5 days), in
agreement with previous reports (case series, Ostroff and
Nelson 1999; Shelton et al 2001). This augmentation effect
is thought to result in part from the blockade of 5-HT2A
receptors and may be explained by the results of animal
studies. The combination of olanzapine and other
antipsychotics with the SSRI fluoxetine produced robust,
sustained increases of extracellular levels of dopamine and
noradrenaline in rat prefrontal cortex and hypothalamus as
measured by microdialysis, greater than with either drug
alone (Zhang et al 2000; Koch et al 2004). Blocking
simultaneously the 5-HT transporter and 5-HT2A receptorsNeuropsychiatric Disease and Treatment 2005:1(4) 306
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Table 2 List of combination/augmentation strategies
Supposed mechanism
Antidepressants Adjunct of action Type of study (reference)
Antidepressant combinations
SSRIs Trazodone Prevention of side-effects by Retrospective prescription analysis (Clark and Alexander 2000)
Nefazodone blockade of 5-HT2A/C receptors
Reboxetine Bupropion Catecholamine boost Review (Stahl 2000) (theoretical)
Desipramine
Venlafaxine Mirtazapine 5-HT and NA boost Prospective and randomized trial (Rush et al 2004)
SSRIs Bupropion-SR 5-HT, NA and DA boost Naturalistic, open-label cohort study (Lam et al 2004)
Uncontrolled clinical series (Bodkin et al 1997); open case series
(Ramasubbu 2002)
Various ECT Probably stimulation of common Retrospective case-controlled study (Gagné et al 2000)
pathways
Various  Psychotherapy Probably stimulation of common Randomized, comparative study (Keller et al 2000); meta-analysis
pathways (Thase et al 1997); randomized, comparative 2-year follow-up
study (Fava et al 1998); open 2-year follow up trial (Fava et al
1997); randomized, comparative 2-year follow up study (Fava et al
1994); controlled trial (Paykel et al 1999); randomized, double-
blind, placebo-controlled trial (Reynolds et al 1999)
SSRIs SAME DA boost Open trial (Alpert et al 2004)
Venlafaxine
Augmentation strategies
TCAs Lithium Second messenger system boost Review (Bauer et al 2003); open trial (Bertschy et al 2003); review
MAOIs Valproate 5-HT boost (Dietrich and Emrich 1998); randomized, double-blind, placebo-
SSRIs Carbamazepine controlled study (Barbosa et al 2003); open study (Ciusani et al
Venlafaxine Lamotrigine 2004)
TCA Thyroid hormone Correction of endocrine Randomized, double-blind, placebo-controlled study (Joffe et al
Fluoxetine dysfunction 1993); meta-analysis (Altshuler et al 2001); open-label treatment
(Agid and Lerer 2003)
Fluoxetine Pindolol Blockade of 5-HT1A  Meta-analysis (Ballesteros and Callado 2004); review (Isaac
Paroxetine autoreceptors (feedback 2004); review (Artigas et al 2001); controlled trial (Pérez et al
removal) 2001); placebo-controlled study (Sokolski et al 2004); double-blind,
placebo-controlled trial (Berman et al 1997)
Fluoxetine Buspirone Stimulation of postsynaptic Open trial (Dimitriou and Dimitriou 1998); review (Shayegan and
Paroxetine 5-HT1A receptors Stahl 2000); randomized, double-blind, placebo-controlled study
Citalopram (Appelberg et al 2001); randomized, double-blind, placebo-
controlled study (Landen et al 1998)
Fluoxetine Estrogen Correction of estrogen Open trial (Rasgon et al 2002); randomized, comparative study
fluctuations (Westlund and Parry 2003); randomized, open-label, parallel trial
(Liu et al 2004)
Nefazodone Metyrapone Inhibition of cortisol synthesis Double-blind, placebo-controlled trial (Jahn et al 2004)
Fluvoxamine (high in depression)
MAOIs Methylphenidate DA boost Review (Feinberg 2004); case study (Shelton Clauson 2004);
Citalopram open-label trial (Lavretsky et al 2003)
Fluoxetine Olanzapine Blockade of 5-HT2A receptors Double-blind, comparative study (Shelton et al 2001);
Paroxetine Ziprasidone Stimulation of 5-HT1A retrospective chart review (Barbee et al 2004); open trial
Citalopram Risperidone receptors (Papakostas et al 2004); case series (Tani et al 2004); case series
Sertraline NA boost (Ostroff and Nelson 1999)
Milnacipran
Abbreviations: DA, dopamine; ECT, electroconvulsive therapy; NA, noradrenaline; SAME, S-adenosyl-l-methionine; SSRIs, selective serotonin reuptake inhibitors.Neuropsychiatric Disease and Treatment 2005:1(4) 307
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has also been shown to enhance synaptic availability of
noradrenaline using in vivo extracellular unitary recordings
(Szabo and Blier 2002). Many atypical antipsychotics also
possess 5-HT1A receptor agonist properties. It is possible
that this characteristic may play a role especially when
associated with an increase in the release of noradrenaline
and dopamine in the prefrontal cortex when antipsychotics
are combined with the SSRIs (Papakostas et al 2004).
Conclusion
Approximately, eight classes of antidepressants acting by
distinct pharmacological mechanisms including over 20
compounds are available to the clinician for the treatment
of depression. The potential combination of any two
compounds is therefore high, which makes for a very
impressive armamentarium to treat depressed patients who
do not respond to antidepressant monotherapy. The exact
nature of the depressive disorder and the type of symptoms
can guide the clinician in choosing the first treatment. The
use of an algorithm can also provide help for adapting and
managing the best combination for a given individual.
Certain combinations such as a MAOI with a drug that
blocks serotonin reuptake should never be used because of
the high risk of inducing a serotonin syndrome (Bijl 2004).
Unfortunately, some combinations and most augmenting
strategies are often based on case reports, very small, open
pilot trials, or even anecdotal findings, which would merit
replication in larger controlled trials. A summary of
combinations and augmentations presented here is given in
Table 2. Lithium, thyroid hormone, and buspirone, which
have been used for a long time, have been the three most
studied combinatory agents. Some of the newer compounds
are promising since they provide ways of boosting
neurotransmission or reducing negative adverse effects
allowing increased doses of the accompanying anti-
depressant. The increased use of this panoply of drug
combinations will hopefully make it easier for clinicians to
overcome the treatment-resistant depression and reach full
recovery in a larger number of patients. The problem is that
there is a lot of rather unstructured data suggesting benefit
from various approaches, but there are very few comparisons
between these approaches. The National Institute of Mental
Health Sequenced Treatment Alternatives to Relieve
Depression (STAR*D) program is an ambitious research
initiative that is intended to generate a much needed
treatment algorithm (Lavori et al 2001; National Institute
of Mental Health 2003; Rush et al 2004). In this study,
approximately 4000 depressed patients will begin treatment
with citalopram at doses up to 60 mg per day. If there is an
inadequate response, they will be randomly assigned to a
variety of treatment options: alternative SSRIs (sertraline),
SNRI (venlafaxine), cognitive therapy alone, or continuation
citalopram with the addition of cognitive therapy, buspirone,
or bupropion augmentation. In case of no response, the next
step of therapy will include switching to nortriptyline or
mirtazapine, or augmentation with lithium or thyroid
hormone. A final phase for ultimate nonresponders will be
random assignment to either tranylcypromine or combined
venlafaxine and mirtazapine. Hopefully, this program should
provide good comparative data and make the clinician’s
choice easier.
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